List view / Grid view
16 December 2025 | By Drug Target Review
AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.
UK life science software company Lab Thread has launched the beta of its unified lab platform, designed to streamline research workflows.
A new survey by the Pistoia Alliance reveals a growing ‘scientific content crisis’ in life sciences, showing that incomplete data and weak governance are limiting the accuracy and adoption of AI in research and development.
Can automation and AI finally make science run at the speed of thought? Eric Ma shares how disciplined systems, not new models, will drive the next wave of discovery.
Nonequilibrium switching (NES) offers a faster, more scalable way to predict how strongly drugs bind to their targets. By replacing slow equilibrium simulations with rapid, parallel transitions, NES delivers accurate free energy predictions at speed.
Demands on central laboratories are consistently increasing, heightening the challenge to deliver operational excellence and the highest standard of scientific integrity with both speed and agility. ICON Laboratories is transforming the way we leverage data and intelligent operational models to meet evolving trial needs.
At ELRIG’s Drug Discovery 2025, Drug Target Review spoke with the teams turning big ideas into usable tools – automation, AI and biology – that help scientists work smarter.
Dublin-based biotech Meta-Flux has raised €1.8M ($2M) in seed funding to expand its AI-driven platform for preclinical drug development, helping researchers predict drug success and accelerate the pathway from lab to clinic.
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
12 August 2025 | By Wuxi Biologics
This expert-led webinar discusses how to break through common bottlenecks in TCR discovery with practical strategies that help teams move faster and smarter.
9 July 2025 | By Eurofins Discovery
Safety data is no longer just a regulatory checkbox - it’s a strategic advantage. Discover how in vitro and computational tools reduce the reliance on animal testing and support smarter, earlier decision-making in drug discovery.
Shift Bioscience has published a new study introducing enhanced metrics and baselines for evaluating virtual cell models - boosting gene target discovery and accelerating its rejuvenation therapeutics pipeline.
Lab scientists and data scientists often speak different languages and that miscommunication can slow down important research. In this interview, Ian Kerman shares how his team is working to break down those walls and spark better collaboration.
Drug development has long been hindered by fragmented data and complex processes, but a new wave of AI is reshaping the landscape. By integrating genomic, clinical and molecular data, multimodal models are revealing hidden patterns and accelerating more precise advancements in medicine.
5 June 2025 | By WuXi Biologics
Stop costly biologic failures. This masterclass reveals high-throughput strategies to optimize antibody leads upfront.
